Edit

drug discovery

Takeda logo on white background

Takeda joins drug target discovery initiative

Takeda joins pioneering public-private drug discover collaboration Open Targets

By Oana Stroe

Lab Matters

This is a portrait of Michael Parker

Fighting disease with structural biology

Alumnus Michael Parker talks about his career, research highlights and how EMBL has played a role

By Margaux Phares

Alumni

Photo of Andrew Leach, Head of Chemical Biology data services at EMBL-EBI

Welcome, Andrew Leach

Q&A with EMBL-EBI's Head of Chemical Biology data services

By Mary Todd Bergman

Science

Futures: Phosphatases

ERC grantee Maja Köhn shares her vision for the next ten years

By Edward Dadswell

Science

Structure of key system for TB infection

EMBL scientists add crucial knowledge to understanding of the bacterium that causes tuberculosis

By Rosemary Wilson

Science

Biogen joins the CTTV

Biogen joins CTTV

Pioneering target validation collaboration expands to accelerate drug discovery research.

By Mary Todd Bergman

Lab Matters

Learning from the linker

Mature cells can be reprogrammed to pluripotency and thus regain the ability to divide and differentiate into specialized cell types. Although these so-called induced pluripotent stem cells (iPS cells) represent a milestone in stem cell research, many of the biochemical processes that underlie…

By Guest author(s)

Science

Open access drug discovery database launches with half a million compounds

ChEMBLdb, a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets, launches today with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new…

By Guest author(s)

Science

Open access to large-scale drug discovery data

The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL’s European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from the publicly listed…

By Guest author(s)

Lab Matters

EMBL scientists found start-up company to develop anti-cancer drugs

Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…

By Guest author(s)

Lab Matters

EMBLetc.

Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive
Edit